Insider Transactions in Q3 2025 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2025
|
Matthew K Fust Director |
SELL
Open market or private sale
|
Direct |
16,000
-41.2%
|
$704,000
$44.75 P/Share
|
|
Sep 26
2025
|
Matthew K Fust Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.48%
|
$10,000
$1.91 P/Share
|
|
Sep 26
2025
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
4,000
-3.64%
|
$180,000
$45.0 P/Share
|
|
Sep 02
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.94%
|
$160,000
$32.1 P/Share
|
|
Sep 02
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.71%
|
$80,000
$16.89 P/Share
|
|
Aug 22
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
30,000
-31.16%
|
$900,000
$30.43 P/Share
|
|
Aug 22
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+23.76%
|
$480,000
$16.89 P/Share
|
|
Aug 20
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
6,492
-8.92%
|
$188,268
$29.18 P/Share
|